---
layout: post
title: "Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments"
date: 2026-02-05 18:59:19 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-11669
original_published: 2022-05-31 00:00:00 +0000
significance: 8.00
---

# Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** May 31, 2022 00:00 UTC
**Document Number:** 2022-11669

## Summary

The Food and Drug Administration (FDA or Agency) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee. The general function of the committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. Members will participate via teleconference. This 2-day virtual meeting will be held to discuss recent requests to amend the Emergency Use Authorization (EUA) of the Moderna COVID-19 mRNA vaccine to include the administration of a primary series to infants, children, and adolescents 6 months through 17 years of age and to amend the EUA of the Pfizer-BioNTech COVID-19 mRNA vaccine to include the administration of a primary series to infants and children 6 months through 4 years of age. The meeting will be open to the public on both days. FDA is establishing a docket for public comment on this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/05/31/2022-11669/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting-establishment-of-a)
- API: https://www.federalregister.gov/api/v1/documents/2022-11669

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
